



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

**STUDIES OF THE MECHANISMS OF RESISTANCE
OF NON-CYCLING CELLS TO
AMSACRINE AND RELATED ANTITUMOUR DRUGS**

A thesis submitted to the University of Auckland

in partial fulfilment of the requirements

for the degree of

Doctor of Philosophy

by

Maxine A. Robbie

Department of Pathology

University of Auckland School of Medicine

April 1988

ABSTRACT

Several studies have shown that non-cycling cells are resistant to the cytotoxic effects induced by amsacrine (*m*-AMSA; 4'-(9-acridinylamino)methanesulphon-*m*-anisidide). This resistance may limit the activity of *m*-AMSA and related 9-anilinoacridine antitumour agents against solid tumours. The biochemical mechanism(s) for this resistance have been investigated using spontaneously transformed Chinese hamster fibroblast (AA8 cells) in log- and plateau-phase spinner cultures. In early plateau phase most cells entered a growth-arrested state with a G₁-G₀ DNA content and showed a marked decrease in sensitivity to cytotoxicity after a 1-h exposure to *m*-AMSA or its solid tumour-active analogue, CI-921. Studies with radiolabelled *m*-AMSA demonstrated that changes in sensitivity to *m*-AMSA-induced cell killing were not due to a difference in uptake or retention of drug by log- and plateau-phase cells, and there was no significant metabolism of drug by either log- or plateau-phase cells. Thus, after a 1-h exposure to [³H]-*m*-AMSA at 37°C, a small proportion (1%) of cell-associated radioactivity was covalently bound to macromolecules, but most of the cell-associated radioactivity represented unchanged *m*-AMSA. There was no evidence for any oxidative metabolism to reactive quinoidal species in these tumour cells. However, studies with a fluorescence assay for DNA unwinding indicated that plateau-phase cells were 3 to 4 times less sensitive to *m*-AMSA-induced DNA breakage than log-phase cells, and changes in sensitivity to *m*-AMSA-induced DNA breakage correlated with changes in sensitivity to cell killing by *m*-AMSA as cell progressed from log to plateau phase. Further studies showed that the decrease in sensitivity to *m*-AMSA-induced DNA strand breakage correlated with a decrease in sensitivity to covalent DNA-protein complex formation in plateau-phase cells after *m*-AMSA treatment. Combined with evidence that the DNA lesions rapidly disappeared from both log- and plateau-phase cells following the removal of *m*-AMSA (half-time approx. 4 min), this indicated that the lesions detected by the FADU assay probably arose from the stimulation of DNA-topoisomerase II (topo II) cleavable complex formation by *m*-AMSA. K⁺/SDS precipitation assays with [³²P] 3'-end-labelled pBR322 DNA indicated that nuclear extracts containing topo II activity from plateau-phase cells were 3- to 4-fold less sensitive to stimulation of DNA-topo II complex formation by *m*-AMSA than nuclear extracts from log-phase cells. This change in sensitivity to *m*-AMSA-induced DNA-topo II complex formation was therefore similar to that observed with intact cells. However, P4 unknotting assays indicated that topo II activity in nuclear extracts from plateau-phase cells was only 2-fold lower than that in nuclear extracts from log-phase cells. Resistance to treatment with *m*-AMSA may therefore reflect a decrease in topo II activity and/or a decrease in sensitivity of topo II enzymes to stimulation of cleavable complex formation by *m*-AMSA in non-cycling cells.

PREFACE

Despite the availability of a steadily increasing number of drugs for the treatment of cancers, most common tumours remain refractory to treatment with existing chemotherapeutic agents (Tattersall, 1981). Although significant advances toward the cure of cancer by chemotherapy have been achieved with cytotoxic agents directed toward some haematopoietic tumours and some rapidly growing tumours, these relatively responsive tumours represent only a small proportion of human cancers. The majority of human cancers are relatively slow-growing solid tumours which respond poorly to existing chemotherapeutic agents (Kennedy *et al.*, 1980).

The present studies were performed under the supervision of Dr W.R. Wilson in the Section of Oncology, Department of Pathology, in association with the Auckland Cancer Research Laboratories, University of Auckland School of Medicine. These studies form part of a wider series of investigations intended to elucidate factors responsible for the resistance of solid tumours toward antitumour agents, particularly those related to the 9-anilinoacridine antitumour drug, amsacrine (*m*-AMSA), which was developed at the Auckland Cancer Research Laboratories.

The development of *m*-AMSA represented a significant achievement since this compound was the first synthetic DNA intercalating agent to be selected for clinical trial as an antitumour agent. However, while *m*-AMSA has proved to have useful therapeutic activity against leukaemias, early clinical trials with this compound indicated that it was ineffective or only marginally effective against a wide range of solid tumours (see section 1.3). A component of the research programme at the Auckland Cancer Research Laboratories is therefore now directed toward the search for analogues of *m*-AMSA with improved therapeutic activity against a broader spectrum of tumours, including both leukaemias and solid tumours. This search currently follows an essentially empirical strategy by seeking correlations between physicochemical properties and biological activity of drugs (Denny *et al.*, 1982). However, it is intended that investigations providing further information on factors limiting the activity of these drugs against solid tumours may provide a more clearly defined basis for the rational design of *m*-AMSA analogues with broad spectrum antitumour properties.

One of the major factors limiting the use of *m*-AMSA in the treatment of solid tumours may be its poor activity against non-cycling cells (Denny *et al.*, 1983c). There is now considerable evidence from *in vitro* studies to suggest that non-cycling cells are much

less sensitive to *m*-AMSA than cycling cells (see section 1.6.2). Evidence that non-cycling cells may also provide a limitation to successful treatment of tumour cells *in vivo* has recently been provided by the demonstration that a variant of the Lewis lung tumour with an elevated proportion of non-cycling cells shows enhanced resistance to *m*-AMSA analogues in mice (Baguley *et al.*, 1985).

This thesis examines possible biochemical mechanisms for resistance of non-cycling cells to *m*-AMSA and investigates whether the resistance of non-cycling cells is also observed with a related 9-anilinoacridine derivative, CI-921, which has demonstrated promising activity against experimental solid tumours. The thesis commences with a comprehensive literature review, which is intended to provide an appreciation of the many factors which may be important in determining the resistance of tumours to antitumour drugs. Since mechanisms of resistance of non-cycling cells to *m*-AMSA may be related to the mode of action of this compound, the review also provides a detailed discussion of the mechanism of cytotoxicity of *m*-AMSA and related 9-anilinoacridine antitumour drugs.

The experimental section of this thesis is presented in chapters 2 to 5. Chapter 2 describes studies performed to characterize an *in vitro* model for non-cycling tumour cells, which was produced by growing transformed Chinese hamster ovary fibroblasts (AA8 cells) to high density (plateau phase) in spinner culture. This chapter also contains results from investigations comparing the differences in sensitivity of cells from log- (cycling) and plateau-phase (non-cycling) cultures to both *m*-AMSA and CI-921. Chapter 3 reports investigations of the metabolism of *m*-AMSA in log- and plateau-phase AA8 cells. The metabolism of *m*-AMSA has not previously been studied in tumour cells. These investigations therefore required the development of an HPLC method which would be capable of detecting several different potential metabolites. Studies performed to characterize this HPLC system are described in detail. Chapter 4 reports studies of the uptake and retention of *m*-AMSA in log- and plateau-phase AA8 cells. Chapter 5 contains results from a series of studies performed to compare the amounts of *m*-AMSA-induced DNA damage in log- and plateau-phase cells and to investigate the mechanisms for the reduced amounts of DNA breakage observed in plateau-phase cells.

The thesis concludes with a general discussion which considers the significance of the material presented in this thesis and includes proposals for future research.

ACKNOWLEDGEMENTS

I would like to express special thanks to Dr Bill Wilson for providing the opportunity for these studies and for his encouragement and careful supervision throughout both the experimental stages of this work and during the preparation of this thesis. I would also like to express sincere thanks to Associate Professor Bruce Baguley for the personal support that he has provided during the course of these studies, and for his help with flow cytometry and with details involved in the presentation of this thesis. In addition, I wish to express my gratitude to Professor John Gavin for conscientious guidance during these studies and for the time that he devoted to reading and editing this thesis.

The help and friendship of many members of the Cancer Research Laboratory have been very important for the completion of this thesis. In particular, I would like to thank Associate Professor Bill Denny and Mr Graeme Atwell for supplying various acridine compounds for use in metabolism studies and for helpful discussions on acridine chemistry. I would also like to thank Dr Brian Palmer for his help with the NMR analysis of glutathione conjugates of *m*-AQI and *m*-AQDI, and Drs Jeff Jurlina and James Paxton (Department of Pharmacology, University of Auckland School of Medicine) for their help in establishing the HPLC assay system for studying the metabolism of *m*-AMSA in AA8 cells. I am very grateful to Mr Robert Lambert for performing the FADU assays to measure DNA breakage in AA8 cells, and to Mrs Susan Pullen, who helped with mitotic index determinations and glutathione assays, and willingly provided technical assistance whenever this was required.

Investigations of the role of topoisomerase II (topo II) enzymes in the resistance of plateau-phase cells to *m*-AMSA-induced cell killing were performed in collaboration with Professor Ray Ralph, Dr Erasmus Schneider and Ms Sandy Darkin from the Department of Cellular and Molecular Biology at the University of Auckland. Both the P4 unknotting assays for topo II strand-passing activity and the *in vitro* assays measuring the formation of covalent DNA-protein complexes in *m*-AMSA-treated cells were performed by Erasmus Schneider. The assays measuring the formation of covalent DNA-protein complexes in *m*-AMSA-treated cells were performed by Sandy Darkin. I wish to thank Erasmus and Sandy for their willing participation in this study and would like to thank Professor Ralph for supporting this collaboration.

Many people have been involved in the final stages of preparation of this thesis. I wish to express my appreciation to Ms Lyn Rogers and Mrs Margaret Snow for their help with word processing. I would also like to thank Ms Lynne Logan and Mr George Baxter for their patient efforts in the preparation of illustrations. In addition, I would like to express my gratitude to Lynne Logan and Ms Sandy Miller for producing the photographs for this thesis.

Finally, I would like to thank my parents for financial assistance during the completion of this thesis. I am indebted to my family and friends, especially Phil, for their patience and understanding during the time that I have devoted to this thesis.

I also wish to express my appreciation to the Auckland Division of the Cancer Society of New Zealand for financial assistance in the form of a PhD Fellowship.

TABLE OF CONTENTS

ABSTRACT	ii
PREFACE	iii
ACKNOWLEDGEMENTS	v
TABLE OF CONTENTS	vii
LIST OF TABLES	xv
LIST OF FIGURES	xvi
LIST OF ABBREVIATIONS	xx
CHAPTER 1	
REVIEW OF LITERATURE	
1.1 INTRODUCTION	1
1.2 CURRENT STATUS OF CHEMOTHERAPY IN THE TREATMENT OF CANCER	2
1.3 THE DEVELOPMENT OF 'BROAD SPECTRUM' ANTITUMOUR DRUGS FOR THERAPY OF SOLID TUMOURS	4
1.4 MECHANISMS OF RESISTANCE OF SOLID TUMOURS TO ANTITUMOUR DRUGS	13
1.4.1 Genetic mechanisms of resistance to antitumour drugs	14
1.4.1.1 Problems arising from the genetic instability of malignant cells	14
1.4.1.2 Biochemical mechanisms for drug resistance	15
1.4.1.3 Pleiotropic drug resistance	16
1.4.2 Mechanisms for resistance arising from structural features of solid tumours	22
1.4.2.1 The structural organization of solid tumours	22
1.4.2.2 Significance of the solid tumour microarchitecture for resistance to various treatment modalities	29
(i) Resistance to radiotherapy	29
(ii) Resistance to chemotherapy	32
1.5 MECHANISM OF ACTION OF <i>m</i> -AMSA AND RELATED ANILINOACRIDINE ANTITUMOUR AGENTS	40
1.5.1 Requirements for DNA binding	41
1.5.2 Inhibition of DNA synthesis	46
1.5.3 Chromosome damage	47
1.5.4 DNA breakage	50

1.6	POSSIBLE REASONS FOR POOR ACTIVITY OF <i>m</i> -AMSA AGAINST SOLID TUMOURS	51
1.6.1	Intrinsic biochemical differences between leukaemia and carcinoma cells	51
1.6.2	Limitations imposed by the structural organization of solid tumours	51
1.7	MECHANISMS FOR RESISTANCE OF NON-CYCLING CELLS TO ANTITUMOUR DRUGS	56
1.8	SUMMARY OF THE REVIEW OF LITERATURE	61
1.9	OBJECTIVES OF THIS THESIS	63

CHAPTER 2

EVALUATION OF PLATEAU-PHASE CULTURES OF AA8 CELLS AS A MODEL FOR STUDYING THE RESISTANCE OF NON-CYCLING CELLS TO *m*-AMSA

2.1	INTRODUCTION	64
2.1.1	Cell culture models for non-cycling tumour cells	64
2.1.2	Plateau-phase suspension cultures of AA8 cells for studying the resistance of non-cycling cells to <i>m</i> -AMSA and related antitumour drugs	67
2.1.3	Objectives of this study	68
2.2	MATERIALS	68
2.2.1	Cells	68
2.2.2	Culture media and supplements	69
2.2.3	Enzyme preparations	70
2.2.4	Drugs	70
2.2.5	Radiochemicals	70
2.2.6	Solvents and other reagents	70
2.3	METHODS	71
2.3.1	Cell density measurements	71
2.3.2	Cell volume measurements	71
2.3.3	Drug treatment and clonogenicity assays	72
2.3.4	Mitotic index determinations	72
2.3.5	Thymidine incorporation	73
2.3.6	Flow cytometry	73

2.4	RESULTS	74
2.4.1	Characterization of plateau-phase cultures of AA8 cells	74
2.4.2	Changes in drug sensitivity during progression toward plateau phase	77
2.5	DISCUSSION	83
2.5.1	Characterization of plateau-phase cultures of AA8 cells	83
2.5.2	The use of plateau-phase AA8 cells as a model for non-cycling cells in solid tumours	86
2.5.3	Resistance of plateau-phase AA8 cells to <i>m</i> -AMSA and CI-921	87
2.6	CONCLUSIONS	90

CHAPTER 3

METABOLISM OF *m*-AMSA IN LOG- AND PLATEAU-PHASE AA8 CELLS

3.1	INTRODUCTION	90
3.1.1	Metabolism of <i>m</i> -AMSA in the blood	90
3.1.2	Metabolism in the liver	96
3.1.3	Biological significance of <i>m</i> -AMSA metabolites	101
	(i) Thiol adducts	101
	(ii) Oxidation products	101
3.1.4	Objectives of this study	102
3.2	MATERIALS	103
3.2.1	Cells	103
3.2.2	Enzymes	103
3.2.3	Drugs	103
3.2.4	Radiochemicals	104
3.2.5	HPLC apparatus	106
3.2.6	Solvents and other reagents	106
3.3	METHODS	106
3.3.1	Synthesis of the glutathione adducts of <i>m</i> -AQI and <i>m</i> -AQDI	106
3.3.2	NMR analysis	106
3.3.3	Spectrophotometric measurements	107
3.3.4	Metabolism studies	107

3.3.5	Recovery of <i>m</i> -AMSA metabolites from AA8 cells using different methods of protein precipitation and metabolite extraction	107
3.3.6	Glutathione assays	109
3.3.7	Clonogenicity assays	110
3.4	RESULTS	111
3.4.1	Characterization of the synthetic products formed by reaction of <i>m</i> -AQI and <i>m</i> -AQDI with GSH	111
	(i) Isolation and purification of the GSH adducts	111
	(ii) NMR analysis	111
	(iii) Absorbance spectra	117
3.4.2	The HPLC Assay System	117
	(i) Chromatographic characteristics of various potential metabolites of <i>m</i> -AMSA	117
	(ii) Instability of <i>m</i> -AQDI on the HPLC column	117
3.4.3	Quantitative extraction of <i>m</i> -AMSA metabolites from cells	123
3.4.4	Metabolism studies with [³ H]- <i>m</i> -AMSA in log- and plateau-phase AA8 cells	127
3.4.4	Metabolism of [³ H]- <i>m</i> -AQDI in AA8 cells	134
3.4.5	Glutathione content of log- and plateau-phase AA8 cells	145
3.4.6	Clonogenicity studies	145
3.5	DISCUSSION	149
3.5.1	HPLC analysis of <i>m</i> -AMSA metabolites	149
	(i) The HPLC method	149
	(ii) Characterization of the GSH adducts of <i>m</i> -AQI and <i>m</i> -AQDI used as standards for HPLC analyses	149
	(iii) Quantitative extraction of <i>m</i> -AMSA metabolites from AA8 cells	152
3.5.2	Glutathione content of log- and plateau-phase AA8 cells	155
3.5.3	Lack of evidence for oxidative metabolism of <i>m</i> -AMSA in log- and plateau-phase AA8 cells	157
3.5.4	The role of metabolism in the cytotoxicity of <i>m</i> -AMSA	159
3.6	CONCLUSIONS	161

CHAPTER 4

UPTAKE AND RETENTION OF *m*-AMSA BY LOG- AND PLATEAU-PHASE AA8 CELLS

4.1	INTRODUCTION	162
4.1.1	Impaired capacity of non-cycling cells for uptake and retention of antitumour drugs	162
4.1.2	Mechanism of transport of <i>m</i> -AMSA across cell membranes	163
4.1.3	Objectives of this study	164
4.2	MATERIALS	165
4.2.1	Cell cultures	165
4.2.2	Drugs	165
4.2.3	Radiochemicals	165
4.2.4	Solvents and other reagents	165
4.3	METHODS	167
4.3.1	Drug uptake studies	167
4.3.2	Drug efflux studies	168
4.3.3	Clonogenicity studies	168
4.3.4	Recovery of cells through silicon oil : liquid paraffin (9:1, v/v)	168
4.3.5	Determination of the amount of extracellular water trapped in cell pellets	169
4.3.6	Determination of the mean volumes of intracellular water in log- and plateau-phase AA8 cells	170
4.3.7	Metabolism studies	171
4.4	RESULTS	171
4.4.1	Clonogenicity studies	171
4.4.2	Recovery of cells by centrifugation through silicon oil : liquid paraffin (9:1, v/v) pre-equilibrated at 20° and at 2°C	172
4.4.3	Volumes of extracellular water trapped in pellets from log- and plateau-phase AA8 cells	172
4.4.4	Volumes of intracellular water in log- and plateau-phase AA8 cells	172
4.4.5	Uptake and efflux of <i>m</i> -AMSA by log- and plateau-phase AA8 cells	174
4.4.6	Formation of covalently-bound macromolecular adducts in log- and plateau-phase AA8 cells	178

4.5	DISCUSSION	178
4.5.1	Uptake of <i>m</i> -AMSA by log- and plateau-phase AA8 cells	178
4.5.2	Slowly-exchanging pools of <i>m</i> -AMSA in log- and plateau-phase AA8 cells	181
4.5.3	Formation of covalently-bound macromolecular adducts at 2° and 37°C	184
4.5.4	A model explaining some of the factors influencing the uptake and efflux of <i>m</i> -AMSA by AA8 cells	185
4.5.5	Differences in sensitivity to <i>m</i> -AMSA-induced cell killing are not due to differences in uptake or retention of <i>m</i> -AMSA by log- and plateau-phase AA8 cells	187
4.6	CONCLUSIONS	187

CHAPTER 5

THE FORMATION OF TOPO II-MEDIATED DNA STRAND BREAKS IN LOG- AND PLATEAU-PHASE AA8 CELLS AFTER TREATMENT WITH *m*-AMSA

5.1	INTRODUCTION	188
5.1.1	Evidence for DNA breakage in mammalian cells after treatment with <i>m</i> -AMSA	188
5.1.2	The origin of protein-associated DNA strand breaks induced by <i>m</i> -AMSA	192
5.1.3	Mechanism of formation of topo II-mediated DNA strand breaks	196
5.1.4	Biological significance of the topo II-associated DNA strand breaks induced by <i>m</i> -AMSA and other DNA intercalating agents	200
5.1.5	Possible mechanisms for differences in sensitivity of log- and plateau-phase AA8 cells to <i>m</i> -AMSA-induced DNA breakage	207
5.1.6	Objectives of this study	209
5.2	MATERIALS	210
5.2.1	Cells	210
5.2.2	DNA	210
5.2.3	Enzymes	210
5.2.4	Radiochemicals	210
5.2.5	Drugs	211
5.2.6	Other reagents	211

5.3	METHODS	211
5.3.1	DNA breakage studies	211
5.3.2	Preparation of nuclear extracts containing topo II activity from log- and plateau-phase AA8 cells	212
5.3.3	The P4 unknotting assay for measurement of topo II catalytic activity	212
5.3.4	Stimulation of covalent DNA-protein complex formation in AA8 cells after treatment with <i>m</i> -AMSA	213
5.3.5	<i>In vitro</i> stimulation of DNA-topo II complex formation using nuclear extracts from log- and plateau-phase AA8 cells	214
5.3.6	Incorporation of [³ H]-TdR into cellular DNA	214
5.4	RESULTS	215
5.4.1	DNA breakage in AA8 cells after treatment with <i>m</i> -AMSA	215
5.4.2	DNA topo II strand-passing activities in log- and plateau-phase AA8 cells	215
5.4.3	Inhibition of P4 unknotting activity by <i>m</i> -AMSA	219
5.4.4	Stimulation of covalent DNA-protein complex formation in log- and plateau-phase AA8 cells after treatment with <i>m</i> -AMSA	219
5.4.5	<i>In vitro</i> stimulation of covalent DNA-topo II complex formation with nuclear extracts from log- and plateau-phase AA8 cells	224
5.5	DISCUSSION	229
5.5.1	Relationship of cytotoxicity to <i>m</i> -AMSA-induced DNA breakage	229
5.5.2	Use of the FADU assay for measuring <i>m</i> -AMSA-induced DNA lesions in mammalian cells	231
5.5.3	Differences in repair of <i>m</i> -AMSA-induced DNA lesions are not responsible for differences in cytotoxicity of <i>m</i> -AMSA toward log- and plateau-phase AA8 cells	232
5.5.4	Decreased cell killing correlates with a decrease in covalent DNA-protein complex formation in plateau-phase AA8 cells after treatment with <i>m</i> -AMSA	234
5.5.5	Changes in chromatin conformation are not responsible for the decrease in sensitivity of plateau-phase cells to DNA-topo II complex formation after treatment with <i>m</i> -AMSA	234
5.5.6	Topo II strand-passing activity in nuclear extracts from log- and plateau-phase AA8 cells	235
5.5.7	Possible mechanisms for resistance of plateau-phase cells to treatment with <i>m</i> -AMSA	238

5.6	CONCLUSIONS	241
-----	-------------	-----

CHAPTER 6

CONCLUDING DISCUSSION

6.1	THE MECHANISM OF RESISTANCE OF NON-CYCLING CELLS TO <i>m</i> -AMSA AND RELATED ANTITUMOUR DRUGS	243
6.2	THE CELLULAR PHARMACOLOGY OF <i>m</i> -AMSA IN TUMOUR CELLS	247
6.2.1	Metabolism studies	247
6.2.2	Uptake and retention of <i>m</i> -AMSA by tumour cells	249
6.3	IMPLICATIONS FOR THE CLINICAL USE OF <i>m</i> -AMSA AND THE DEVELOPMENT OF RELATED 9-ANILINOACRIDINE ANTITUMOUR DRUGS FOR THE TREATMENT OF SOLID TUMOURS	255

APPENDICES

APPENDIX I.	Commercial sources and grades of solvents used	259
APPENDIX II.	Commercial sources and grades of reagents used	260

REFERENCES	263
------------	-----

PUBLICATION

LIST OF TABLES

TABLE	PAGE
1.1 Biochemical mechanisms for resistance of tumours to antitumour drugs	17
3.1 HPLC characteristics of <i>m</i> -AMSA and potential metabolites on a reverse-phase C ₁₈ Novapak column, using a mobile phase of 18% MeCN containing 10 mM TEAP, pH 3.0, at a flow rate of 2.5 ml/min, with absorbance detectors at wavelengths of 254 and 436 nm	119
3.2 Recovery of <i>m</i> -AMSA metabolites from AA8 cells using different methods for protein precipitation and extraction of metabolites	124
3.3 Recovery of <i>m</i> -AMSA metabolites from the MeCN-soluble fraction from AA8 cells	125
3.4 Radioactivity recovered after adding [³ H]- <i>m</i> -AQDI (1 nmol) to AA8 cells at varying stages during preparation for HPLC analysis	126
3.5 Recovery of radioactivity in successive wash fractions (MeCN, 90% v/v) from AA8 cells, after exposing to [³ H]- <i>m</i> -AMSA (1 μM) for 1 h at 37°C	131
3.6 Recovery of radioactivity from suspensions of AA8 cells (10 ⁷ /ml) in PBS at varying times after addition of [³ H]- <i>m</i> -AQDI (10 μM)	146

LIST OF FIGURES

FIGURE	PAGE
1.1 The molecular structures of Adriamycin and daunorubicin	5
1.2 The molecular structure of 9-anilinoacridine	7
1.3 The molecular structures of <i>m</i> -AMSA and other AMSA analogues	9
1.4 Schematic representation of the growth of a solid tumour from a single cell	23
1.5 The Thomlinson-Gray model of the solid tumour cord in cross-section	26
1.6 Diagrammatic representation of the organization of subpopulations of tumour cells with respect to distance from the nearest blood vessel in the solid tumour	28
1.7 Diagram showing the effect of oxygen in sensitizing cells to damage induced by ionizing radiation	31
1.8 Kinetic model of a cell population	38
2.1 Growth curve for AA8 cells maintained in spinner culture in Alpha MEM supplemented with 10% FCS plus antibiotics at 37°C	75
2.2 Changes in proliferation state of AA8 cells growing in suspension culture at 37°C	76
2.3 DNA histograms showing changes in cell cycle distribution of AA8 cells from log- and plateau-phase spinner cultures	78
2.4 Changes in the proportions of AA8 cells in various stages of the cell cycle during growth in spinner culture at 37°C	79
2.5 Cell volume distributions determined by Coulter analysis of AA8 cells from log- and plateau-phase spinner cultures	80
2.6 Changes in mean volume of AA8 cells determined by analysis of Coulter counter pulse heights at various stages during growth in spinner culture at 37°C	81
2.7 Clonogenicity of untreated AA8 cells and sensitivity to <i>m</i> -AMSA at different stages during growth in spinner culture at 37°C	82
2.8 Changes in sensitivity of AA8 cells to CI-921 at different stages during growth in spinner culture at 37°C	84
2.9 Survival curves for AA8 cells after 1-h exposures to <i>m</i> -AMSA at different stages during growth in spinner culture at 37°C	85
3.1 Proposed thiolytic reaction mechanism for the formation of acridinyl adducts from <i>m</i> -AMSA	93

3.2	Postulated pathway for the formation of protein adducts by addition of protein thiols to the 5'-position of the anilino ring of <i>m</i> -AMSA	95
3.3	Scheme showing various metabolic pathways of <i>m</i> -AMSA involving conjugation with GSH and hydrolysis	97
3.4	HPLC chromatograms of the glutathione conjugates of <i>m</i> -AQDI obtained using a reverse-phase C ₁₈ Novapak column and a mobile phase of 18% MeCN containing 10 mM TEAP, pH 3.0, at a flow rate of 2.5 ml/min	112
3.5	HPLC chromatograms of the glutathione conjugates of <i>m</i> -AQDI obtained using a reverse-phase C ₁₈ Novapak column and a mobile phase of 15% MeCN containing 10 mM TEAP, pH 3.0, at a flow rate of 2.5 ml/min	113
3.6	¹ H-NMR spectrum of the glutathionyl adduct of <i>m</i> -AQI	115
3.7	¹ H-NMR spectra of species formed by reaction of GSH with <i>m</i> -AQDI	116
3.8	Absorbance spectra of 5'-GS- <i>m</i> -AMSA and 6'-GS- <i>m</i> -AMSA	118
3.9	Representative HPLC chromatograms obtained by analysis of components of the standard spike solution (25 μl) containing <i>m</i> -AMSA and potential metabolites	120
3.10	Radioactivity profiles obtained by HPLC analysis of [³ H]- <i>m</i> -AQDI using a reverse-phase C ₁₈ Novapak column and a mobile phase of 18% MeCN containing 10 mM TEAP, pH 3.0, at a flow rate of 2.5 ml/min	121
3.11	HPLC chromatograms obtained after adding [³ H]- <i>m</i> -AQDI to a lysed preparation of AA8 cells prior to extraction and protein precipitation with MeCN (90%, v/v)	128
3.12	HPLC chromatograms obtained by analysis of the MeCN-soluble material from a lysed preparation of untreated AA8 cells	129
3.13	HPLC chromatograms obtained by analysis of Alpha MEM (225 μl)	130
3.14	HPLC chromatograms showing retention times of MeCN-soluble species contained in the first wash fraction from log-phase AA8 cells after incubation with [³ H]- <i>m</i> -AMSA (1 μM) for 1 h at 37°C	132
3.15	HPLC chromatograms showing retention times of MeCN-soluble species contained in the first wash fraction from plateau-phase AA8 cells after incubation with [³ H]- <i>m</i> -AMSA (1 μM) for 1 h at 37°C	133
3.16	HPLC chromatograms showing retention times of MeCN-soluble radioactive species derived from log- and plateau-phase AA8 cells after incubation with [³ H]- <i>m</i> -AMSA for 1 h at 37°C	135
3.17	HPLC chromatograms demonstrating the instability of [³ H]- <i>m</i> -AQDI in Alpha MEM	137
3.18	HPLC chromatograms showing retention times of MeCN-soluble species derived from AA8 cells at various times during incubation with [³ H]- <i>m</i> -AQDI (10 μM) in PBS at 37°C	142

3.19	Changes in glutathione content of AA8 cells during growth in spinner culture at 37°C	147
3.20	Survival curves for log- and plateau-phase AA8 cells after 30-min exposures to <i>m</i> -AQI and <i>m</i> -AQDI in PBS at 37°C	148
3.21	Revised scheme showing the chemical structures of the synthetic species formed by reaction of glutathione with <i>m</i> -AQDI and <i>m</i> -AQI	150
3.22	Scheme showing the pathways for metabolism of <i>m</i> -AQDI in AA8 cells	154
4.1	The proportion (%) of AA8 cells recovered after centrifugation through silicon oil : liquid paraffin (9:1, v/v) at 9,000 x <i>g</i> for varying periods of time (min) following pre-incubation of the oil mixture at 20° or 2°C	186
4.2	Representative profiles showing total radioactivity associated with log- and plateau-phase AA8 cells at various times during incubation with [¹⁴ C]- <i>m</i> -AMSA at 37°C	175
4.3	Representative profiles of the uptake and egress kinetics of [¹⁴ C]- <i>m</i> -AMSA at 37°C	176
4.4	Representative profiles of the uptake and egress kinetics of [¹⁴ C]- <i>m</i> -AMSA at 2°C	177
4.5	Formation of covalently bound macromolecular adducts during incubation of log-phase AA8 cells with [³ H]- <i>m</i> -AMSA (1 μM) at 2° or 37°C	179
4.6	Diagram showing some of the factors influencing the uptake and efflux of <i>m</i> -AMSA by AA8 cells	191
5.1	The DNA 'strand passing' reaction mediated by DNA topoisomerase II	193
5.2	Some DNA topoisomerization reactions catalysed by topo II enzymes on double-stranded DNA	195
5.3	Model for <i>m</i> -AMSA-induced DNA cleavage by DNA topoisomerase II	198
5.4	Fluorescence assay of DNA unwinding (FADU) after treatment of AA8 cells with <i>m</i> -AMSA for 1 h at 37°C	216
5.5	Relationship between sensitivity to DNA breakage and cell density, and between cell killing and cell density	217
5.6	Time course of disappearance of DNA lesions after removal of <i>m</i> -AMSA	218
5.7	DNA topo II strand-passing activity in nuclear extracts from log- and plateau-phase AA8 cells	220
5.8	Inhibition of P4 unknotting activity of nuclear extracts from log- and plateau-phase AA8 cells by <i>m</i> -AMSA	222
5.9	Effect of specific activity on the rate of incorporation of [³ H]-TdR into cellular DNA	225

5.10	Effect of total thymidine concentration on [³ H]-TdR incorporation into AA8 cells	226
5.11	Effect of [³ H]-TdR on growth of AA8 cells	227
5.12	Stimulation of covalent DNA-protein complex formation in log- and plateau-phase AA8 cells after treatment with <i>m</i> -AMSA	228
5.13	Stimulation of DNA-topo II complex formation with nuclear extracts from log- and plateau-phase AA8 cells and [³² P] 3'-end-labelled pBR322 DNA	230

LIST OF ABBREVIATIONS

9-AA	9-aminoacridine
AAMP	4'-(9-acridinylamino)-3'-methoxyphenol
ADP-ribose	adenosine(5')diphospho(5')- β -D-ribose
ALL	acute lymphoblastic leukaemia
Alpha MEM	Alpha modified minimal essential medium
AML	acute myelogenous leukaemia
AMSA	4'-(9-acridinylamino)methanesulphonanilide
9-AO	9(10H)-acridone
$[\alpha\text{-}^{32}\text{P}]\text{-dATP}$	deoxyadenosine 5'- $[\alpha\text{-}^{32}\text{P}]\text{triphosphate}$
<i>aprt</i>	adenine phosphoribosyl transferase
ara-C	1- β -D-arabinofuranosyl cytosine
AT	ataxia-telangiectasia
ATP	adenosine 5'-triphosphate
BCNU	1,3-bis(2-chloroethyl)-1-nitrosourea
BSA	bovine serum albumin
cDNA	complementary DNA
CHO	Chinese hamster ovary (cells)
CI-921	<i>N</i> ,5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenyl-amino]-4-acridinecarboxamide
$[\text{}^{14}\text{C}]\text{-inulin}$	$[\textit{carboxyl-}^{14}\text{C}]\text{-carboxyl inulin}$
$[\text{}^{14}\text{C}]\text{-}m\text{-AMSA}$	$[\textit{9-acridinyl-}^{14}\text{C}]\text{-}m\text{-AMSA}$
C.V.	coefficient of variation
D_0	mean lethal dose
DAPI	4',6'-diamidino-2-phenylindole
dATP	2'-deoxyadenosine 5'-triphosphate
$d_6\text{-DMSO}$	hexadeuteriodimethylsulphoxide
DFMO	α -difluoromethylornithine
dGTP	2'-deoxyguanosine 5'-triphosphate
DMF	dimethylformamide
DMSO	dimethyl sulphoxide
DNAase	deoxyribonuclease
DNP	deoxynucleoprotein
DOC	deoxycholate
DPC	DNA-protein cross-link
DSB	(DNA) double-strand break

DTNB	5,5'-dithiobis-(2-nitrobenzoic acid)
DTT	1,4-dithiothreitol
dTTP	2'-deoxythymidine 5'-triphosphate
ECG	electrocardiogram
EDTA	ethylenediamine tetraacetic acid
EGTA	ethyleneglycol bis(β -aminoethyl ether)- <i>N,N'</i> -tetraacetic acid
FADU	fluorescence assay for DNA unwinding
FCS	foetal calf serum
FD	field desorption (mass spectrometry)
g.i.	gastrointestinal
9-GS-A	<i>S</i> -(9-acridinyl)-glutathione thioether
6'-GS-AAMP	4'-(9-acridinylamino)-6'-(<i>S</i> -glutathionyl)-3'-methoxyphenol
GSH	reduced glutathione
5'-GS- <i>m</i> -AMSA	4'-(9-acridinylamino)-5'-(<i>S</i> -glutathionyl)-3'-methoxymethanesulphonanilide
6'-GS- <i>m</i> -AMSA	4'-(9-acridinylamino)-6'-(<i>S</i> -glutathionyl)-3'-methoxymethanesulphonanilide
GS-MSA	<i>S</i> -[4-amino-3-methoxymethanesulphonanilid-5-yl]-glutathione
GSSG	oxidized glutathione
[³ H]- <i>m</i> -AMSA	[<i>acridinyl-G</i> ³ H]- <i>m</i> -AMSA
[³ H]- <i>m</i> -AQDI	[<i>acridinyl-G</i> ³ H]- <i>m</i> -AQDI
HMG	high mobility group (protein)
¹ H-NMR	proton nuclear magnetic resonance
³ H ₂ O	tritiated water
HPLC	high performance liquid chromatography
<i>hprt</i>	hypoxanthine phosphoribosyl transferase
<i>hsp</i>	heat shock protein
[³ H]-TdR	[5- <i>methyl</i> - ³ H] thymidine
HU	hydroxyurea
5-ID	5-iminodaunorubicin
i.p.	intraperitoneal
i.v.	intravenous
LDS	lithium dodecyl sulphate
<i>m</i> -AMSA	4'-(9-acridinylamino)methanesulphon- <i>m</i> -anisidide
<i>m</i> -AQDI	<i>N</i> 1'-methanesulphonyl- <i>N</i> 4'-(9-acridinyl)-3'-methoxy-2',5'-cyclodexadiene-1',4'-diimine
<i>m</i> -AQI	3'-methoxy-4'-(9-acridinylamino)-2',5'-cyclohexadien-1'-one

MeCN	acetonitrile
2-Me-9-OH-E ⁺	2-methyl-9-hydroxyellipticinium
MI	mitotic index
MSA	4-amino-3-methoxymethanesulphonanilide
NAD	nicotinamide adenine dinucleotide
NADPH	nicotinamide adenine dinucleotide phosphate, reduced
NPSH	non-protein sulphydryl
<i>o</i> -AMSA	4'-(9-acridinylamino)methanesulphon- <i>o</i> -anisidide
PALA	<i>N</i> -(phosphonoacetyl)-L-aspartic acid
PBS	phosphate-buffered saline
PCSII/AA	PCSII containing 1% acetic acid
PDR	pleiotropic drug resistance
PEG	polyethylene glycol
Pha	phytohaemagglutinin
pHe	extracellular pH
pHi	intracellular pH
PLD	potential lethal damage
PLDR	potential lethal damage repair
PLM	percent labelled mitoses
poly (ADP-ribose)	polymer of ADP-ribose
POPOP	1,4-bis-[2-(5-phenyloxazolyl)]benzene
PPO	2,5-diphenyloxazole
NCI	National Cancer Institute
NMR	nuclear magnetic resonance
QSAR	quantitative structure-activity relationship
SAR	structure-activity relationship
s.c.	subcutaneous
SCE	sister chromatid exchange
S.D.	standard deviation
SDS	sodium dodecyl sulphate
S.E.	standard error
SSB	(DNA) single-strand break
TAF	tumour angiogenesis factor
TCA	trichloroacetic acid
TdR	thymidine
TEAP	triethylammonium phosphate
TLC	thin layer chromatography

TMS	tetramethylsilane
topo I	DNA topoisomerase I (EC 5.99.1.2)
topo II	DNA topoisomerase II (EC 5.99.1.3)
Tris	tris (hydroxymethyl)aminomethane
XP	xeroderma pigmentosum